IGF1 and neoplasm: Although inhibition of IGF signaling pathway has shown promising anti-tumor activity in pre-clinical studies, clinical trials of IGFR inhibitors, including neutralizing antibodies to IGF, receptor-blocking antibodies, and small-molecule IGFR kinase inhibitors, have only limited success [27].